374 related articles for article (PubMed ID: 8888955)
1. Nuclear areas in breast cancer: relationship with estrogen and progesterone receptor expression.
Maiorana A; Cavallari V; Bagni A; Ussia F; Maiorana MC; Fano RA
Anal Cell Pathol; 1996 Aug; 11(3):199-209. PubMed ID: 8888955
[TBL] [Abstract][Full Text] [Related]
2. [Expression and intranuclear distribution of nucleolin in estrogen receptor-negative and estrogen receptor-positive breast cancers in women measured by laser scanning cytometry].
Masiuk M
Ann Acad Med Stetin; 2006; 52(2):23-32. PubMed ID: 17633394
[TBL] [Abstract][Full Text] [Related]
3. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.
Leers MP; Hoop JG; van Beers M; van Rodijnen N; Pannebakker M; Nap M
Cytometry B Clin Cytom; 2005 Mar; 64(1):43-52. PubMed ID: 15668953
[TBL] [Abstract][Full Text] [Related]
4. Sex steroid receptors, S-phase fraction and DNA ploidy as determinants of the risk of relapse and death of female breast cancer.
Lipponen P; Eskelinen M; Papinaho S; Klemi PJ; Aaltomaa S; Kosma VM; Marin S; Syrjänen K
Anticancer Res; 1992; 12(3):677-82. PubMed ID: 1622125
[TBL] [Abstract][Full Text] [Related]
5. Biochemically estrogen receptor-negative, progesterone receptor-positive breast carcinoma. Immunocytochemical hormone receptors and prognostic factors.
Keshgegian AA
Arch Pathol Lab Med; 1994 Mar; 118(3):240-4. PubMed ID: 8135626
[TBL] [Abstract][Full Text] [Related]
6. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
7. [Immunohistochemical investigation of steroid hormones (ER, PR) in breast cancer].
Mchedlishvili MIu; Gabunia UA; Makharoblidze ER; Burnadze KT; Piradashvili DZ
Georgian Med News; 2005 Feb; (119):65-7. PubMed ID: 15834186
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry.
van Agthoven T; Timmermans M; Foekens JA; Dorssers LC; Henzen-Logmans SC
Am J Pathol; 1994 Jun; 144(6):1238-46. PubMed ID: 7515559
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters.
Thike AA; Chng MJ; Fook-Chong S; Tan PH
Pathology; 2001 Feb; 33(1):21-5. PubMed ID: 11280603
[TBL] [Abstract][Full Text] [Related]
10. Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer.
Neven P; Van Calster B; Van den Bempt I; Van Huffel S; Van Belle V; Hendrickx W; Decock J; Wildiers H; Paridaens R; Amant F; Leunen K; Berteloot P; Timmerman D; Van Limbergen E; Weltens C; Van den Bogaert W; Smeets A; Vergote I; Christiaens MR; Drijkoningen M
Breast Cancer Res Treat; 2008 Jul; 110(1):153-9. PubMed ID: 17687649
[TBL] [Abstract][Full Text] [Related]
11. Assessment of results of estrogen and progesterone receptor assays performed in a community hospital.
Szakacs JG; Arroyo JG; Girgenti AJ
Ann Clin Lab Sci; 1986; 16(4):266-73. PubMed ID: 3740795
[TBL] [Abstract][Full Text] [Related]
12. [Immunohistochemical characteristics of mammary carcinomas with estrogen-negative and progesterone-positive receptors].
Sundblad AS; Caprarulo L
Medicina (B Aires); 1996; 56(6):683-9. PubMed ID: 9284572
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor-negative, progesterone receptor-positive breast carcinoma: poor clinical outcome.
Keshgegian AA; Cnaan A
Arch Pathol Lab Med; 1996 Oct; 120(10):970-3. PubMed ID: 12046611
[TBL] [Abstract][Full Text] [Related]
14. Comparison of an immunocytochemical assay for progesterone receptor with a biochemical method of measurement and immunocytochemical examination of the relationship between progesterone and estrogen receptors.
Berger U; Wilson P; Thethi S; McClelland RA; Greene GL; Coombes RC
Cancer Res; 1989 Sep; 49(18):5176-9. PubMed ID: 2766287
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
16. Estrogen and progesterone receptors status in Thai female breast cancer patients: an analysis of 399 cases at King Chulalongkorn Memorial Hospital.
Lertsanguansinchai P; Chottetanaprasith T; Chatamra K; Sampatanukul P; Wannakrairot P; Rojpornpradit P; Shotelersuk K; Lertbutsayanukul C; Boonjunwetwat D; Vajragupta L
J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S193-202. PubMed ID: 12188412
[TBL] [Abstract][Full Text] [Related]
17. Interobserver reproducibility of immunocytochemical estrogen- and progesterone receptor status assessment in breast cancer.
Biesterfeld S; Veuskens U; Schmitz FJ; Amo-Takyi B; Böcking A
Anticancer Res; 1996; 16(5A):2497-500. PubMed ID: 8917341
[TBL] [Abstract][Full Text] [Related]
18. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.
Van Calster B; Vanden Bempt I; Drijkoningen M; Pochet N; Cheng J; Van Huffel S; Hendrickx W; Decock J; Huang HJ; Leunen K; Amant F; Berteloot P; Paridaens R; Wildiers H; Van Limbergen E; Weltens C; Timmerman D; Van Gorp T; Smeets A; Van den Bogaert W; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 Jan; 113(1):181-7. PubMed ID: 18264760
[TBL] [Abstract][Full Text] [Related]
19. Expression of c-erbB-2 in node negative breast cancer does not correlate with estrogen receptor status, predictors of hormone responsiveness, or PCNA expression.
Kolár Z; Murray PG; Zapletalová J
Neoplasma; 2002; 49(2):110-3. PubMed ID: 12088102
[TBL] [Abstract][Full Text] [Related]
20. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
